Swedish Orphan Biovitrum (Sobi) has been rated the UK’s top haemophilia company for 2016, despite only launching its first treatments in the area midway through the way.
The firm’s Cambridge, UK-based affiliate won plaudits for being a “transparent and trustworthy company” according to IPC Associates’ long-running annual survey.
Paul Cox, Sobi’s business unit director haemophilia for the UK and Ireland, said: “On behalf of the therapeutic area of haemophilia at Sobi, I welcome this survey outlining Sobi as an ethical and a trustworthy company.
“One of our primary strategies last year was to earn the trust of everyone involved with haemophilia in the UK via a credible scientific but practical approach to all our interactions. The results of this survey help us believe we’re doing the right thing, and will continue to do so in the future.”
IPC Associates has run its independent annual survey for over 20 years to compare UK companies supplying fully licensed coagulation products, products on clinical trial, or those under marketing/clinical investigation.
Last year 12 companies were ranked, based on confidential interviews with healthcare professionals working in haemophilia treatment centres as well as people working for patient support groups.
Sobi scored between ‘very good’ and ‘outstanding’ in 70 percent of activities, particularly shining when it came to product range, quality/safety and the state of the art nature of its offering.
The Stockholm-headquartered company last year launched two haemophila treatments in the UK - Elocta for the treatment of haemophilia A and Alprolix for the treatment of haemophilia B.